Tel Aviv, Israel-based Biobeat Technologies, Ltd. has closed a $50 million Series B equity financing to support the commercial expansion of its patch-worn, cuff-less 24-hour ambulatory blood pressure monitoring (ABPM) system in the United States. The company develops what it says is the first FDA-cleared ABPM solution that replaces traditional inflatable cuffs with a disposable, wearable sensor.
The funding round was led by new investors Ally Bridge Group, OrbiMed Advisors, and Elevage Medical, with participation from a strategic investor. As part of the transaction, representatives from the three lead investors—Steven Plachtyna of Ally Bridge, Dina Chaya of OrbiMed, and Evan Melrose of Elevage—have joined Biobeat’s board of directors.
Biobeat plans to use the proceeds to scale commercialization efforts in the U.S., including expanding its field sales organization. The company is targeting wider adoption of ambulatory blood pressure monitoring, a clinical tool widely regarded as the gold standard for diagnosing hypertension but one that has historically seen limited use.
Traditional cuff-based ABPM devices require repeated inflation throughout the day and night, which can disrupt patients’ daily activities and sleep. These limitations have contributed to lower patient compliance and created logistical challenges for healthcare providers, including device management and data collection. Biobeat’s approach replaces cuffs with a lightweight, patch-worn sensor that continuously measures blood pressure over a 24-hour period without inflating.
According to the company, patients can carry on normal activities and sleep without interruption while wearing the device. After the monitoring period is complete, the patch is disposed of, and a comprehensive report is generated automatically and made available within seconds through the institution’s electronic medical record system.
Raymond W. Cohen, Executive Chairman of Biobeat, said the company expects its technology to change how ambulatory blood pressure monitoring is used in clinical practice. He compared its potential impact to the shift seen in ambulatory ECG monitoring following the introduction of patch-based devices, which significantly increased clinical adoption.
Arik Ben Ishay, Chief Executive Officer of Biobeat, said the financing comes at a pivotal time as the company moves from validation to broader market deployment. He added that the company’s goal is to establish cuff-less ABPM as a standard of care for diagnosing hypertension and guiding treatment decisions, particularly medication titration.
Hypertension affects more than 100 million people in the United States, and improved monitoring methods are increasingly seen as critical to better diagnosis, management, and long-term cardiovascular outcomes.
